Analysis
Gilead Sciences appears significantly less exposed to the U.S. "reciprocal" or "Liberation Day" tariffs introduced in April 2025 compared to its pharmaceutical peers. This resilience is primarily due to the company's differentiated structural approach, with more than 80% of its profits recognized in the United States and the vast majority of its intellectual property (IP) held domestically. While management initially identified potential indirect cost increases for items such as steel, lab supplies, chemicals, and reagents, these impacts were characterized as manageable and were navigated within the company's existing FY2025 financial guidance.
To mitigate the risk of direct tariffs on pharmaceutical imports, Gilead entered into a drug pricing agreement with the U.S. government in December 2025. Under this agreement, Gilead committed to lowering Medicaid pricing for certain products and reinforcing its commitment to U.S.-based manufacturing innovation. In exchange, the company received a three-year exemption from pharmaceutical-specific tariffs. This strategy effectively traded potential import duty costs for a more predictable, though still impactful, revenue headwind.
The primary financial impact of this tariff mitigation strategy is a projected 2% headwind to HIV sales growth in FY2026. This headwind, which includes the effects of the December 2025 pricing agreement and proposed changes to the Affordable Care Act (ACA), is expected to reduce total HIV business growth from a potential 8% to approximately 6% year-over-year. Based on FY2025 HIV sales of $20.8B, this represents a net revenue impact of approximately $415M for the upcoming year.
As part of its long-term mitigation and commitment to U.S. innovation, Gilead has significantly ramped up its domestic investment. The company broke ground on a new Pharmaceutical Development and Manufacturing Technical Development Center in California as part of a broader $32B planned investment in the U.S. through 2030. This domestic reshoring effort is intended to further insulate the company from future trade-related disruptions and ensure compliance with the terms of its tariff exemption.
Data
FY2026 Revenue Impact of Policy and Tariff Mitigation
($M)
| Revenue Metric | FY2025A | FY2026E | y/y Growth |
|---|---|---|---|
| HIV Product Sales | $20,752 | $21,997 | 6.0% |
| Impact of Pricing/Policy Agreement | -- | (415) | (2.0%) |
| HIV Sales (Ex-Policy Impact) | $20,752 | $22,412 | 8.0% |
| Total Base Business Revenue | $28,004 | $29,000 – $29,400 | 3.6% – 5.0% |
Note: The 2.0% headwind includes the December 2025 drug pricing agreement (tariff mitigation) and ACA updates. FY2026E base business revenue reflects midpoint guidance of $29.2B.
Source: Transcript FY-2025, Annual Report FY-2025, Marvin Labs
Financial Impact
- Revenue Impact (Forward-Looking): $415M
Sources
The 'vast majority' of the company’s intellectual property is in the U.S. and more than 80% of profits are recognized in its home country... Gilead is already better positioned than many large drugmakers to stave off the effects of industry-specific tariffs.
In total, these headwinds [drug pricing agreement and ACA changes] are expected to impact HIV growth by about 2% in 2026 compared to 2025. Absent these headwinds, our HIV business is expected to grow 8% in 2026.
The known tariffs that have been enacted to date may increase some of our indirect costs, but we expect them to be manageable in 2025, in part due to our strong operating expense discipline.